losartan has been researched along with cyclosporine in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (14.29) | 18.2507 |
| 2000's | 25 (51.02) | 29.6817 |
| 2010's | 13 (26.53) | 24.3611 |
| 2020's | 4 (8.16) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Avdeef, A; Tam, KY | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Norman, BH | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Andoh, TF; Bennett, WM; Burdmann, EA; Coffman, TM; Connors, BA; Evan, A; Lindsley, J; Nast, CC | 1 |
| Auch-Schwelk, W; Duske, E; Fleck, E; Hess, B; Hildebrandt, AG; Klein, U; Regitz-Zagrosek, V; Steffen, C | 1 |
| Chiu, SH | 1 |
| Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE | 1 |
| Bravo, J; Campistol, JM; Capdevilla, L; del Castillo, D; Guirado, L; Martínez, JG; Pereira, P; Pérez, R | 1 |
| Boran, M; Cetin, S; Gönen, F | 1 |
| Fu, M; Liu, N; Pang, Y; Su, J; Tang, C; Xu, S; Zhang, J | 1 |
| Grabs, R; Olbrich, HG; Richter, H; Richter, M; Schramm, D; Skupin, M | 1 |
| Böhmig, G; Gruber, U; Köller, E; Mayer, G; Schmidt, A | 1 |
| Azzollini, N; Benigni, A; Gagliardini, E; Marchetti, G; Mister, M; Noris, M; Perico, N; Pezzotta, A; Remuzzi, G | 1 |
| Ahn, HJ; Bang, BK; Kim, J; Kim, SK; Kim, WY; Kim, YO; Kim, YS; Park, JH; Shin, MJ; Yang, CW | 1 |
| Kamper, AL; Nielsen, AH | 1 |
| Demura, M; Mabuchi, H; Takeda, Y; Usukura, M; Yoneda, T | 1 |
| Kellems, RE; Wen, HY; Xia, Y | 1 |
| Cappello, D; Francesco, L; Morale, W; Puliatti, C; Puliatti, D; Valvo, C; Veroux, M; Veroux, P | 1 |
| Armada, E; Gayoso, P; Otero Glz, A; Pérez Melón, C | 1 |
| Andoh, TF; Bennett, WM; Isaac, J; Shihab, FS; Yi, H | 1 |
| Gerhardt, U; Hillebrand, U; Hohage, H; Kobelt, V; Matzkies, F; Sindermann, J; Suwelack, B; vOphoven, M | 1 |
| Mohr, FW; Olbrich, HG; Richter, HR; Richter, MH | 1 |
| Ahn, HJ; Bang, BK; Cha, JH; Jung, JY; Kim, J; Kim, WY; Kim, YS; Li, C; Yang, CW; Yoon, SA | 1 |
| Ishikawa, A; Kawabe, K | 1 |
| Bräsen, JH; Budde, K; Dragun, D; Fritsche, L; Luft, FC; Neumayer, HH; Schönemann, C; Wallukat, G | 1 |
| Bennett, T; Fallgren, B; Gardiner, SM; Kemp, PA; March, JE | 1 |
| Bang, BK; Choi, BS; Kim, IS; Kim, YS; Lee, SH; Li, C; Lim, SW; Sun, BK; Yang, CW | 1 |
| Ishikawa, A; Kawabe, K; Kitamura, T; Ohta, N; Ozono, S | 1 |
| Cha, JH; Kang, DH; Kang, SW; Kim, J; Kim, YS; Li, C; Lim, SW; Song, JC; Sun, BK; Yang, CW | 1 |
| Biedunkiewicz, B; Chamienia, A; Rutkowski, B; Tylicki, L; Wojnarowski, K; Zdrojewski, Z | 1 |
| Ishikawa, A; Kitamura, T; Ohta, N; Ozono, S; Tanaka, M | 1 |
| Inamdar, MN; Kumar, NP; Venkataraman, BV | 1 |
| Chen, J; Cheng, M; Ding, X; Han, F; Le, Y; Xu, L; Zhang, L; Zhu, X | 1 |
| Günzel, C; Marx, N; Mischke, K; Noor-Ebad, F; Rana, OR; Saygili, E; Schauerte, P; Schwinger, RH | 1 |
| Komiyama, T; Momota, R; Naito, I; Narasaki, M; Ninomiya, Y; Ohtsuka, A | 1 |
| Jeong, HJ; Kim, JH; Kim, PK; Lee, YH; Lim, BJ; Shin, JI | 1 |
| El-Din, MM; El-Mas, MM; Elmallah, AI; Khedr, MM; Nasser, SA; Sabra, R | 1 |
| Hassan, S; Orentas, M; Patel, N; Rodby, R | 1 |
5 review(s) available for losartan and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
The use of in vitro metabolism studies in the understanding of new drugs.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Cells, Cultured; Cyclosporine; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Imidazoles; Liver; Losartan; Tetrazoles | 1993 |
The association between adult-onset Still's disease and collapsing glomerulopathy: a case report.
Topics: Adolescent; Adult; Cyclosporine; Female; Fever; Humans; Kidney Diseases; Kidney Failure, Chronic; Losartan; Prednisone; Still's Disease, Adult-Onset | 2022 |
7 trial(s) available for losartan and cyclosporine
| Article | Year |
|---|---|
Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cyclosporine; Drug Interactions; Female; Humans; Hypertension, Renal; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Losartan; Male; Postoperative Complications; Tacrolimus | 1998 |
The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Cyclosporine; Enalapril; Female; Homeostasis; Humans; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Losartan; Male; Middle Aged; Potassium; Prospective Studies; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Uric Acid | 2001 |
Uricosuric effect of losartan in patients with renal transplants.
Topics: Adult; Angiotensin Receptor Antagonists; Cross-Over Studies; Cyclosporine; Drug Administration Schedule; Female; Humans; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Losartan; Male; Middle Aged; Reference Values; Uric Acid | 2001 |
Beneficial effect of losartan against proteinuria from the renal allograft.
Topics: Adolescent; Antihypertensive Agents; Child; Child, Preschool; Cyclosporine; Humans; Immunosuppressive Agents; Kidney Transplantation; Losartan; Proteinuria; Transplantation, Homologous | 2003 |
Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Creatinine; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Transplantation; Losartan; Male; Middle Aged; Nifedipine; Plasminogen Activator Inhibitor 1; Tetrazoles; Transplantation, Homologous | 2005 |
Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients.
Topics: Albuminuria; Blood Pressure; Carbazoles; Carvedilol; Cyclosporine; Female; Humans; Kidney Function Tests; Kidney Transplantation; Losartan; Male; Middle Aged; Placebos; Propanolamines | 2006 |
Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Case-Control Studies; Cyclosporine; Female; Humans; Hyperuricemia; Immunosuppressive Agents; Kidney Transplantation; Losartan; Male; Middle Aged; Polycythemia; Prospective Studies; Receptor, Angiotensin, Type 1; Safety; Uric Acid | 2009 |
37 other study(ies) available for losartan and cyclosporine
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril.
Topics: Animals; Biphenyl Compounds; Blood Pressure; Cyclosporine; Enalapril; Furosemide; Hydralazine; Imidazoles; Kidney; Kidney Diseases; Losartan; Male; Microscopy, Electron, Scanning; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger; Tetrazoles | 1995 |
Tissue- and subtype-specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin-converting enzyme inhibitors and AT1 antagonists.
Topics: Administration, Oral; Adrenal Cortex; Adrenal Medulla; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Cyclosporine; Down-Regulation; Drug Interactions; Imidazoles; Kidney; Lisinopril; Liver; Losartan; Male; Pyridines; Quinolines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Angiotensin; Tetrazoles; Up-Regulation | 1995 |
Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Apoptosis; Arginine; Biotin; Cyclosporine; Deoxyuracil Nucleotides; DNA Fragmentation; Enzyme Inhibitors; Fibrosis; Hydralazine; Immunosuppressive Agents; Ischemia; Kidney; Losartan; Macrophages; Male; Nephritis, Interstitial; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Staining and Labeling | 1998 |
Losartan in renal allograft recipients receiving cyclosporine A.
Topics: Adult; Angiotensin Receptor Antagonists; Cyclosporine; Drug Evaluation; Erythropoiesis; Female; Hematocrit; Hemoglobins; Humans; Kidney Transplantation; Losartan; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Uric Acid | 1999 |
Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats.
Topics: Angiotensin II; Animals; Animals, Newborn; Atrial Natriuretic Factor; Calcineurin; Calcineurin Inhibitors; Calcium; Cardiomegaly; Cell Division; Cells, Cultured; Cyclosporine; DNA; Fibroblasts; Fura-2; Hyperplasia; Losartan; Myocardium; Protein Kinase C; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Signal Transduction | 1999 |
New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Disease; Coronary Vessels; Cyclosporine; Enalapril; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Losartan; Male; Premedication; Rats; Rats, Inbred F344; Rats, Inbred Lew; Transplantation, Heterotopic | 2000 |
Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Chronic Disease; Creatinine; Cyclosporine; Drug Therapy, Combination; Graft Rejection; Graft Survival; Hemodynamics; Immunohistochemistry; Immunosuppressive Agents; Kidney; Kidney Transplantation; Losartan; Mycophenolic Acid; Proteinuria; Rats; Rats, Inbred F344; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Renal Circulation; Transplantation, Homologous; Transplantation, Isogeneic | 2001 |
Influence of the renin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney.
Topics: Angiotensin II; Animals; Apoptosis; Blood Pressure; Cyclosporine; Diet, Sodium-Restricted; Epidermal Growth Factor; Fibrosis; Immunohistochemistry; In Situ Nick-End Labeling; Kidney Glomerulus; Losartan; Male; Rats; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System | 2001 |
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
Topics: Aldosterone; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Natriuretic Factor; Body Weight; Calcineurin; Calcineurin Inhibitors; Cardiomegaly; Collagen Type III; Cyclosporine; Enzyme Inhibitors; Fibrosis; Heart; Immunosuppressive Agents; Losartan; Male; Mineralocorticoids; Myocardium; Nephrectomy; Organ Size; Rats; Rats, Inbred WKY; RNA, Messenger; Sodium Chloride, Dietary; Tacrolimus | 2002 |
Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation.
Topics: Angiotensin II; Calcineurin; Cell Line; Cyclosporine; DNA-Binding Proteins; Embryo Implantation; Gene Expression Regulation; Humans; Losartan; NFATC Transcription Factors; Nuclear Proteins; Plasminogen Activator Inhibitor 1; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; RNA, Messenger; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Trophoblasts | 2002 |
[Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cyclosporine; Drug Evaluation; Female; Follow-Up Studies; Hematocrit; Humans; Immunosuppressive Agents; Kidney Transplantation; Lisinopril; Losartan; Male; Polycythemia; Postoperative Complications; Retrospective Studies | 2002 |
[Uricemia-lowering activity of losartan in kidney transplantation].
Topics: Adult; Cyclosporine; Drug Evaluation; Erythroid Precursor Cells; Erythropoietin; Humans; Immunosuppressive Agents; Kidney Transplantation; Kidney Tubules; Losartan; Middle Aged; Polycythemia; Postoperative Complications; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renal Circulation; Treatment Outcome; Uric Acid | 2002 |
Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cyclosporine; Disease Models, Animal; Enalapril; Endothelial Growth Factors; Extracellular Matrix Proteins; Gene Expression; Immunosuppressive Agents; Intercellular Signaling Peptides and Proteins; Kidney Diseases; Losartan; Lymphokines; Male; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
Influence of antihypertensive drugs on renal microcirculation and renal hemodynamics in cyclosporine A-treated rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cyclosporine; Hemodynamics; Immunosuppressive Agents; Isoquinolines; Laser-Doppler Flowmetry; Losartan; Male; Microcirculation; Quinapril; Rats; Rats, Wistar; Renal Circulation; Tetrahydroisoquinolines | 2002 |
Two good reasons for an angiotensin-II type 1 receptor blockade with losartan after cardiac transplantation: reduction of incidence and severity of transplant vasculopathy.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Coronary Artery Disease; Cyclosporine; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Incidence; Losartan; Models, Animal; Postoperative Complications; Rats; Rats, Inbred F344; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Severity of Illness Index | 2003 |
Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Body Weight; Chronic Disease; Cyclosporine; Drug Synergism; Fibrosis; Gene Expression; Immunosuppressive Agents; Kidney; Kidney Diseases; Losartan; Macrophages; Male; Mycophenolic Acid; Osteopontin; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sialoglycoproteins; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor.
Topics: Acute Disease; Adrenal Cortex Hormones; Angiotensin II Type 1 Receptor Blockers; Antibody Formation; Biopsy; Cyclosporine; Drug Therapy, Combination; Graft Rejection; Humans; Imidazoles; Immunoglobulin G; Immunosuppressive Agents; Kidney Transplantation; Losartan; Major Histocompatibility Complex; Mycophenolic Acid; Pyridines; Receptor, Angiotensin, Type 1 | 2003 |
Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cyclosporine; Drug Interactions; Heart Rate; Hemodynamics; Immunosuppressive Agents; Indans; Infusions, Intravenous; Losartan; Male; Phentolamine; Propranolol; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Renal Circulation; Sirolimus; Tacrolimus | 2004 |
Blockade of angiotensin II with losartan attenuates transforming growth factor-beta1 inducible gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Northern; Cyclosporine; Disease Models, Animal; Extracellular Matrix Proteins; Immunoblotting; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization; Losartan; Male; Nephritis, Interstitial; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Transforming Growth Factor beta1; Up-Regulation | 2005 |
Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy.
Topics: Animals; C-Reactive Protein; Cyclosporine; Disease Models, Animal; Fibrosis; Inflammation; Kidney; Kidney Diseases; Losartan; Male; Pravastatin; Rats; Rats, Sprague-Dawley | 2005 |
Prevention of interstitial fibrosis of renal allograft by angiotensin II blockade.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Cyclosporine; Female; Fibrosis; Humans; Immunosuppressive Agents; Kidney Transplantation; Losartan; Male; Middle Aged; Postoperative Complications | 2006 |
Comparative interaction of few antihypertensive drugs with cyclosporine-A in rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta, Thoracic; Chromatography, High Pressure Liquid; Cyclosporine; Diltiazem; Drug Interactions; Enalapril; Losartan; Male; Olive Oil; Plant Oils; Propranolol; Rats; Rats, Wistar | 2007 |
Irregular electrical activation of intrinsic cardiac adrenergic cells increases catecholamine-synthesizing enzymes.
Topics: Animals; Calcineurin Inhibitors; Catecholamines; Coculture Techniques; Cyclosporine; Dopamine beta-Hydroxylase; Electric Stimulation; Endothelin A Receptor Antagonists; Epinephrine; Losartan; Metoprolol; Myocardium; Myocytes, Cardiac; NFATC Transcription Factors; Peptides, Cyclic; Rats; Signal Transduction; Tacrolimus; Tyrosine 3-Monooxygenase | 2011 |
Drosophila type XV/XVIII collagen mutants manifest integrin mediated mitochondrial dysfunction, which is improved by cyclosporin A and losartan.
Topics: Animals; Collagen Type XVIII; Cyclosporine; Drosophila; Integrins; Losartan; Mice; Mice, Knockout; Mitochondria; Reactive Oxygen Species | 2013 |
Influence of cyclosporine A on glomerular growth and the effect of mizoribine and losartan on cyclosporine nephrotoxicity in young rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Histocytochemistry; Kidney; Kidney Diseases; Kidney Glomerulus; Losartan; Male; Rats, Sprague-Dawley; Ribonucleosides | 2016 |
Facilitation by the renin-angiotensin system of cyclosporine-evoked hypertension in rats: Role of arterial baroreflexes and vasoreactivity.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Angiotensin II; Animals; Aorta; Atrasentan; Baroreflex; Blood Pressure; Captopril; Cyclosporine; Hypertension; Indomethacin; Losartan; Male; Naphthalenes; Nitric Oxide Synthase Type III; Nitroprusside; Oligopeptides; Phenylephrine; Piperidines; Propionates; Pyrrolidines; Rats; Renin-Angiotensin System; Vasoconstriction; Vasodilation | 2016 |